3 research outputs found
Epidemiology and antimicrobial resistance trends of Acinetobacter species in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data
Introduction: Acinetobacter spp., in particular A. baumannii, are opportunistic pathogens linked to nosocomial pneumonia (particularly ventilator-associated pneumonia), central-line catheter-associated blood stream infections, meningitis, urinary tract infections, surgical-site infections, and other types of wound infections. A. baumannii is able to acquire or upregulate various resistance determinants, making it frequently multidrug-resistant, and contributing to increased mortality and morbidity. Data on the epidemiology, levels, and trends of antimicrobial resistance of Acinetobacter spp. in clinical settings is scarce in the Gulf Cooperation Council (GCC) and Middle East and North Africa (MENA) regions. Methods: A retrospective 12-year analysis of 17,564 non-duplicate diagnostic Acinetobacter spp. isolates from the United Arab Emirates (UAE) was conducted. Data was generated at 317 surveillance sites by routine patient care during 2010-2021, collected by trained personnel and reported by participating surveillance sites to the UAE National AMR Surveillance program. Data analysis was conducted with WHONET. Results: Species belonging to the A. calcoaceticus-baumannii complex were mostly reported (86.7%). They were most commonly isolated from urine (32.9%), sputum (29.0%), and soft tissue (25.1%). Resistance trends to antibiotics from different classes during the surveillance period showed a decreasing trend. Specifically, there was a significant decrease in resistance to imipenem, meropenem, and amikacin. Resistance was lowest among Acinetobacter species to both colistin and tigecycline. The percentages of multidrug-resistant (MDR) and possibly extensively drug-resistant (XDR) isolates was reduced by almost half between the beginning of the study in 2010 and its culmination in 2021. Carbapenem-resistant Acinetobacter spp. (CRAB) was associated with a higher mortality (RR: 5.7), a higher admission to ICU (RR 3.3), and an increased length of stay (LOS; 13 excess inpatient days per CRAB case), as compared to Carbapenem-susceptible Acinetobacter spp. Conclusion: Carbapenem-resistant Acinetobacter spp. are associated with poorer clinical outcomes, and higher associated costs, as compared to carbapenem-susceptible Acinetobacter spp. A decreasing trend of MDR Acinetobacter spp., as well as resistance to all antibiotic classes under surveillance was observed during 2010 to 2021. Further studies are needed to explore the reasons and underlying factors leading to this remarkable decrease of resistance over time
The use of multiplex real-time PCR improves the detection of the bacterial etiology of community acquired pneumonia
Community-acquired pneumonia (CAP) is still a major cause of morbidity and
mortality especially to children and compromised hosts, such as the old and those with
underlying chronic diseases. Knowledge of pathogens causing CAP constitutes the basis for
selection of antimicrobial treatment. Previous data have shown that etiological agents can
be identified in only up to 50% of patients, but this figure can be improved by using polymerase
chain reaction (PCR). This study was designed to evaluate multiplex real-time PCR as a
method for rapid differential detection of five bacterial causes of CAP (Streptococcus
pneumoniae, Burkholderia pseudomallei and atypical bacterial pathogens namely Mycoplasma
pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila) in CAP patients
attending Hospital Tengku Ampuan Afzan (HTAA)/ Kuantan, Pahang, Malaysia. Two previously
developed multiplex real-time PCR assays, duplex for the differential detection of S.
pneumoniae and B. pseudomallei and triplex for the atypical bacterial pathogens, were used
to detect a bacterial cause of CAP in blood and respiratory samples. Thus, 46 blood and 45
respiratory samples collected from 46 adult CAP patients admitted to HTAA were analysed by
multiplex real-time PCR assays and conventional methods. The microbial etiology of CAP
could be established for 39.1% (18/46) of CAP patients by conventional methods and this was
increased to 65.2% (30/46) with the additional use of real-time PCR. The most frequently
detected pathogens were S. pneumoniae (21.7% - all by PCR alone), Klebsiella pneumoniae
(17.3%), B. pseudomallei (13% - 83% of them positive by PCR alone and 17% by both culture
and PCR), Pseudomonas aeruginosa (6.5%), M. pneumoniae (6.5% - all by serology), C.
pneumoniae (4.3% - all positive by both PCR and serology), L. pneumophila (2.1% - all by PCR
alone), Escherichia coli (4.3%). Haemophilus infuenzae, Acinetobacter lwoffii and
Acinetobacter baumannii were detected by conventional methods (2.1% for each)
A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways
(1) Background: Today, the discovery of novel anticancer agents with multitarget effects and high safety margins represents a high challenge. Drug discovery efforts indicated that benzopyrane scaffolds possess a wide range of pharmacological activities. This spurs on building a skeletally diverse library of benzopyranes to identify an anticancer lead drug candidate. Here, we aim to characterize the anticancer effect of a novel benzopyrane derivative, aiming to develop a promising clinical anticancer candidate. (2) Methods: The anticancer effect of SIMR1281 against a panel of cancer cell lines was tested. In vitro assays were performed to determine the effect of SIMR1281 on GSHR, TrxR, mitochondrial metabolism, DNA damage, cell cycle progression, and the induction of apoptosis. Additionally, SIMR1281 was evaluated in vivo for its safety and in a xenograft mice model. (3) Results: SIMR1281 strongly inhibits GSHR while it moderately inhibits TrxR and modulates the mitochondrial metabolism. SIMR1281 inhibits the cell proliferation of various cancers. The antiproliferative activity of SIMR1281 was mediated through the induction of DNA damage, perturbations in the cell cycle, and the inactivation of Ras/ERK and PI3K/Akt pathways. Furthermore, SIMR1281 induced apoptosis and attenuated cell survival machinery. In addition, SIMR1281 reduced the tumor volume in a xenograft model while maintaining a high in vivo safety profile at a high dose. (4) Conclusions: Our findings demonstrate the anticancer multitarget effect of SIMR1281, including the dual inhibition of glutathione and thioredoxin reductases. These findings support the development of SIMR1281 in preclinical and clinical settings, as it represents a potential lead compound for the treatment of cancer